Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Norucholic acid dose-finding in primary biliary cholangitis with inadequate response to ursodeoxycholic acid
NL-OMON53827Phase 2Terminated
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of norursodeoxycholic acid in primary biliary cholangitis (PBC) (3 arms), sponsored by Dr. Falk Pharma GmbH. Primary endpoint: Mean relative change in alkaline phosphatase at end of treatment. Started Nov 2022; status: terminated.
02
Drugs
norursodeoxycholic acid
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NL-OMON53827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53827.